(Q47440559)

English

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

scientific article published on 2 November 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

10

object named as

Seock-Ah Im

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

16

object named as

Narikazu Boku

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

author name string

Rui-Hua Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Keisho Chin

3

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Keun-Wook Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Se Hoon Park

5

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Sun Young Rha

6

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Lin Shen

7

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Shukui Qin

8

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Nong Xu

9

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Gershon Locker

11

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Phil Rowe

12

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Xiaojin Shi

13

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Darren Hodgson

14

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Yu-Zhen Liu

15

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

publication date

2 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

18

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

12

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

1637-1651

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Characteristics of gastric cancer in Asia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the DNA Damage Response in Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA damage-induced activation of ATM and ATM-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The heterochromatic barrier to DNA double strand break repair: how to get the entry visa

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Efficiency of Cox's Likelihood Function for Censored Data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Covariance analysis of censored survival data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930682-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30682-4

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 January 2018

http://europepmc.org/abstract/MED/29103871

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47440559&oldid=2157811506"